Drug Monograph

Drug/Drug Class:	**Apadaz™ (benzhydrocodone/acetaminophen) tablet/ Short Acting Combination Opioids**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Apadaz is available in tablet form in the following strengths: 4.08/325 mg, 6.12/325 mg, and 8.16/325 mg of benzhydrocodone/acetaminophen.
Manufacturer:	Distributed by: KemPharm, Inc., Coralville, IA 52241.
Indications:	Apadaz is indicated for short-term (less than or equal to 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It should be reserved for use in patients for whom alternative treatment options (eg, nonopioid analgesics) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
Costs:	$0.64 per 4.08/325 mg tablet, $0.72 per 6.12/325 mg tablet, and $0.71 per 8.16/325 mg tablet of Apadaz. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends adding this drug to the current Short Acting Combination Opioids Clinical Edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Preferred ☒ Appropriate Indications ☐ No PA Required

Prepared by: Jaci Schowengerdt, PharmD
Date: May 15th, 2019

© 2019 Conduent Business Services, LLC All Rights Reserved.